CymaBay Therapeutics Inc. (CBAY) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
7575 GATEWAY BOULEVARD NEWARK, CA 94560 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 135,500 | 194,600 | 146,300 | 190,900 | 178,700 | 97,200 | |||
| Cash and cash equivalents | 20,291 | 125,806 | 28,193 | 24,869 | 48,995 | 23,054 | |||
| Short-term investments | 115,194 | 60,729 | 118,130 | 166,076 | 129,669 | 74,156 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 15 | 8,065 | (23) | (45) | 36 | (10) | |||
| Receivables | 5,000 | ||||||||
| Prepaid expense | 2,193 | 2,764 | 1,381 | 2,594 | 1,208 | ||||
| Other current assets | 304 | 126 | |||||||
| Other undisclosed current assets | 2,573 | (5,694) | 2,521 | 10,642 | (36) | 10 | |||
| Total current assets: | 138,073 | 191,099 | 151,585 | 202,923 | 181,562 | 103,544 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | ✕ | ✕ | |||||||
| Operating lease, right-of-use asset | 169 | 254 | 272 | 235 | ✕ | ✕ | |||
| Property, plant and equipment | 701 | 1,178 | 1,761 | 2,409 | 2,905 | 69 | |||
| Long-term investments and receivables | 8,067 | ||||||||
| Long-term investments | 8,067 | ||||||||
| Other noncurrent assets | 2,909 | 1,720 | 207 | 160 | 2,280 | 634 | |||
| Total noncurrent assets: | 3,779 | 11,219 | 2,240 | 2,804 | 5,185 | 703 | |||
| TOTAL ASSETS: | 141,852 | 202,318 | 153,825 | 205,727 | 186,747 | 104,247 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 14,690 | 12,600 | 8,910 | 7,238 | 5,827 | 7,111 | |||
| Interest and dividends payable | ✕ | ✕ | 43 | ||||||
| Employee-related liabilities | ✕ | ✕ | 3,986 | 3,769 | 2,013 | ||||
| Accounts payable | 1,096 | 2,728 | 231 | 2,503 | 1,973 | 1,311 | |||
| Accrued liabilities | 13,594 | 5,886 | 4,910 | 2,722 | 3,854 | 5,757 | |||
| Deferred revenue | ✕ | ✕ | |||||||
| Debt | 407 | 3,108 | |||||||
| Restructuring reserve | 18 | 3,193 | |||||||
| Other undisclosed current liabilities | 751 | 5,766 | 929 | 6,798 | 8,588 | 6,091 | |||
| Total current liabilities: | 15,441 | 18,366 | 9,857 | 17,636 | 14,415 | 16,310 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 695 | 1,262 | 1,743 | 2,990 | |||||
| Long-term debt, excluding current maturities | 2,990 | ||||||||
| Finance lease, liability | ✕ | ✕ | |||||||
| Liabilities, other than long-term debt | 30 | 1,914 | |||||||
| Deferred revenue | ✕ | ✕ | |||||||
| Deferred rent credit | 1,914 | ✕ | |||||||
| Operating lease, liability | 30 | 695 | 1,262 | 1,743 | ✕ | ✕ | |||
| Other undisclosed noncurrent liabilities | 90,227 | 49,625 | (1,262) | ||||||
| Total noncurrent liabilities: | 90,257 | 51,015 | 1,262 | 1,743 | 1,914 | 2,990 | |||
| Total liabilities: | 105,698 | 69,381 | 11,119 | 19,379 | 16,329 | 19,300 | |||
| Equity | |||||||||
| Equity, attributable to parent | 36,154 | 132,937 | 142,706 | 186,348 | 170,418 | 84,947 | |||
| Common stock | 8 | 8 | 7 | 7 | 6 | 4 | |||
| Additional paid in capital | 909,329 | 899,798 | 819,549 | 812,133 | 693,534 | 535,503 | |||
| Accumulated other comprehensive income (loss) | (326) | (13) | 8 | 80 | (58) | (44) | |||
| Accumulated deficit | (872,857) | (766,856) | (676,858) | (625,872) | (523,064) | (450,516) | |||
| Total equity: | 36,154 | 132,937 | 142,706 | 186,348 | 170,418 | 84,947 | |||
| TOTAL LIABILITIES AND EQUITY: | 141,852 | 202,318 | 153,825 | 205,727 | 186,747 | 104,247 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 10,000 | |||||||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 10,000 | |
| Gross profit: | 10,000 | |||||||
| Operating expenses | (93,111) | (87,582) | (52,602) | (108,150) | (72,505) | (31,325) | ||
| Operating loss: | (93,111) | (87,582) | (52,602) | (108,150) | (72,505) | (21,325) | ||
| Nonoperating income (expense) | (12,890) | (2,416) | 1,616 | 5,342 | (43) | (5,152) | ||
| Investment income, nonoperating | 2,017 | 167 | 1,616 | 5,342 | 3,988 | 621 | ||
| Other nonoperating income (expense) | (3,288) | (5,773) | ||||||
| Interest and debt expense | (14,907) | (2,895) | (407) | (1,080) | ||||
| Loss from continuing operations: | (120,908) | (92,893) | (50,986) | (102,808) | (72,955) | (27,557) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (92,893) | (50,986) | (102,808) | (72,955) | (27,557) | |
| Other undisclosed net income | 14,907 | 2,895 | 407 | |||||
| Net loss available to common stockholders, basic: | (106,001) | (89,998) | (50,986) | (102,808) | (72,548) | (27,557) | ||
| Dilutive securities, effect on basic earnings per share | (422) | |||||||
| Net loss available to common stockholders, diluted: | (106,001) | (89,998) | (50,986) | (102,808) | (72,970) | (27,557) | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (106,001) | (89,998) | (50,986) | (102,808) | (72,548) | (27,557) | ||
| Other comprehensive income (loss) | (313) | (21) | (72) | 138 | (14) | (43) | ||
| Comprehensive loss, net of tax, attributable to parent: | (106,314) | (90,019) | (51,058) | (102,670) | (72,562) | (27,600) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.